Novel Predictor Of Mortality In Patients Undergoing Transcatheter Aortic Valve Implantation

OBJECTIVE: There are no reliable biomarkers for short- or long-term outcome prediction in patients undergoing transcatheter aortic valve implantation (TAVI). Our goal was to investigate whether presepsin is also suited for risk assessment in TAVI patients. The aim of this study was to assess whether Presepsin, a novel marker indicative for sepsis, has prognostic value in the postoperative outcome in patients after transcatheter aortic valve implantation (TAVI).